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Context: Epidemiological studies have indicated that high serum
levels of GH and IGF-I are associated with long-term risks.
Objective: The objective of the study was to evaluate the changes in
serum levels of GH during overnight profiles, IGF-I, and IGF binding
protein 3 (IGFBP-3) in short small for gestational age (SGA) children
during GH treatment with two doses.
Patients: Thirty-six prepubertal short SGA children were the sub-
jects of this study.
Intervention: Subjects received 1 (group A) or 2 (group B) mg
GH/m2d.
Main Outcome Measures: At baseline and after 6 months of GH
treatment, overnight GH profiles were performed, and serum IGF-I
and IGFBP-3 levels were measured.
Results: After 6 months, group B had significantly higher GH levels
during the profile (mean, maximum, and area under the curve above
zero line) than group A (P  0.009). In group B, maximum GH levels
increased from 43.9–161 mU/liter (P 0.0002), and in group A, from
57.2–104 mU/liter (P  0.002). During the profile (i.e. 12 h per day),
children of group B had mean GH levels of 64.4 vs. 34.8 mU/liter in
group A (P  0.001). The IGF-I and IGF-I to IGFBP-3 ratio SD scores
increased significantly in both groups, but were higher in group B
thanA [1.5 vs. 0.2 (P 0.002) and 1.4 vs. 0.3 (P 0.007), respectively].
In groupB, 74%of the children had IGF-I levels in the highest quintile
during GH treatment compared with 19% in group A.
Conclusion: Our study shows that high-dose GH treatment in short
SGA children results in high serum GH and IGF-I levels in most
children. We recommend monitoring IGF-I levels during GH therapy
to ensure that these remain within the normal range. (J Clin En-
docrinol Metab 91: 1390–1396, 2006)
MOST CHILDREN BORN small for gestational age(SGA) show catch-up growth to a normal height
during the first 2 yr of life, but approximately 10–15% of
them remain short with a height below 2 sd scores (1, 2).
Disturbances in the GH/IGF axis may play a role in SGA
children with persistent short stature (3–10).
It has been demonstrated that GH treatment of short chil-
dren born SGA results in a normalization of height during
childhood, as well as a normal adult height for most of them
(6, 11). Recently, Van Pareren et al. (11) showed that long-
term treatment with a GH dose of 1 mg/m2d (0.033 mg/
kgd) was as effective as the higher dose of 2 mg/m2d
(0.067/kgd) for most children with regard to adult height.
Previous reports have shown that GH treatment of short
SGA children leads to increases in serum IGF-I and IGF
binding protein 3 (IGFBP-3) levels, which are positively re-
lated to the GH dose (4–6). Sas et al. (6) reported a rise of the
IGF-I and IGFBP-3 sd score up to 1.2 and 0.2, respectively,
during GH treatment with 1 mg GH/m2d for 1 yr, whereas
treatment with 2 mg GH/m2d resulted in an IGF-I and
IGFBP-3 sd score of 1.9 and 0.5, respectively. After 5 yr of GH
treatment, the IGF-I and IGFBP-3 sd scores were 1.7 and 1.0
in the 1-mgGHdose group and to 2.0 and 1.2 in the 2-mgGH
dose group, respectively (6).
Although the effects of GH treatment on serum levels of
IGF-I and IGFBP-3 in short SGA children have been well
studied, no data are available on the effect of GH therapy
with various doses on serum GH levels in these children. It
has been shown that administration of GH to healthy and
GH-deficient adults results in a dose-dependent rise of se-
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rum GH levels (12, 13). Therefore, it is expected that short
SGA children receiving high-dose GH treatment not only
have higher levels of IGF-I, but also higher GH levels.
Concern has been expressed regarding the possible harm-
ful effects of high serum GH and IGF-I levels for many years
(14, 15). Recent epidemiological studies on risk of breast (16),
prostate (17), and colon (18) cancer have indicated that serum
levels of IGF-I in the upper tertile to quintile are associated
with an increased risk of cancer. For that reason, it is im-
portant to evaluate the serum levels of GH and IGF-I in
GH-treated short SGA children.
Therefore, we studied GH levels during an overnight GH-
profile and serum levels of IGF-I and IGFBP-3 in 36 short
SGA children, both before and after 6 months of treatment
with either 1 or 2 mg GH/m2d.
Subjects and Methods
Subjects
The study group comprised 36 prepubertal short children born SGA.
Children were included according to the following criteria: 1) birth
length and/or birth weight sd score (sd score) below 2 for gestational
age, 2) current height sd score below 2.5, 3) height velocity sd score
below zero to exclude children with spontaneous catch-up growth, 4)
prepubertal stage, defined as Tanner breast stage I for girls and testicular
volume less than 4ml for boys, 5) age between 5–8 yr at start of the study,
and 6) an uncomplicated neonatal period, without signs of severe as-
phyxia (Apgar score 3 after 5 min) or long-term complications of
respiratory ventilation such as bronchopulmonary dysplasia. Children
with endocrine or metabolic disorders, chromosomal defects, syn-
dromes, and growth failure caused by other conditions (e.g. emotional
deprivation, severe chronic illness, chondroplasia) were excluded, ex-
cept for childrenwith Silver-Russell syndrome. The studywas approved
by the medical ethics committees of the participating centers, and writ-
ten informed consent was obtained from the parents.
Study design
After stratification for gender, GH-status (maximum serum GH be-
tween 20–30 mU/liter vs. serum GH 30 mU/liter during a GH stim-
ulation test), and body mass index (BMI) (1 sd vs. 1 sd), all 36
children were randomized into two different groups. During 6 months,
children of group A (n  16) received GH therapy with a dose of 1 mg
GH/m2d and children of group B (n  20) received a dose of 2 mg
GH/m2d. GH [Nordiptropin * SimpleXx 15 mg/1.5 ml (biosynthetic
human growth hormone,NovoNordiskA/S, Bagsvaerd, Denmark]was
administered sc once daily at bedtime using the Nordipen 15. Overnight
GHprofileswere performed in all subjects at baseline and after 6months
of GH treatment. Children were admitted to the hospital, and blood for
determination of serum GH levels was withdrawn from an indwelling
venous catheter at 20-min intervals between 1900 and 0700 h. Children
followed their normal eating pattern until midnight. The next morning
a fasting blood sample was taken formeasurement of IGF-I and IGFBP-3
levels. During the second GH profile, at 6 months after start of GH
therapy, the daily sc GH injectionwas given under observation at 2000 h,
1 h after onset of the GH profile.
Assays
Serum IGF-I and IGFBP-3 were measured using a specific RIA (19) in
one laboratory. The intraassay coefficient of variation (CV) was 4% and
the interassayCVwas 6%.GH levelsweremeasured by IMMULITE 2000
(Diagnostic Products Corporation, Los Angeles, CA), with a lower de-
tection limit of 0.13 mU/liter. The intraassay and interassay CVwere 3.7
and 5.7%, respectively.
Calculations
All overnight GH profiles were analyzed using the Pulsar program
(20). The area under the curve above zero line (AUC0), mean, and
maximum GH levels were derived. The AUC0 was divided by three to
rescale time into units of 1 h, and was similar when calculated by the
trapezoidalmethod. Serum levels ofGHwere expressed inmilliunits per
liter. The serum levels of IGF-I and IGFBP-3 were converted into sd
scores to adjust for age and sex, using reference values for healthy
children with normal stature determined in the same laboratory (21).
Statistics
Analyses were carried out using the computer statistical package
SPSS (version 10.1; SPSS Inc., Chicago, IL) for Windows. Results are
expressed as the median (interquartile range), unless indicated other-
wise. The Mann-Whitney U test was used for differences between
groups. Differences between points in time were tested by theWilcoxon
signed rank test. To test for linear relationships between continuous
variables, partial correlations were estimated for group A and B to-
gether, with adjustment for GH dosage. Multiple linear regression anal-
ysis was used to assess multivariable relationships. Factors showing a
significant partial correlationwith the 6-month change in height sd score
were entered into the model. Only results of the best fitting model (in




Table 1 lists the baseline clinical data of both GH dosage
groups. Children of both groups (A and B) had comparable
baseline characteristics. Two children of group B had genet-
ically proven Silver-Russell syndrome. Six children in group
A and six children in group B were born preterm.
Growth response to GH therapy
In group A, the height sd score increased significantly
from 3.3 (3.4 to 2.8) at start to 2.8 (2.9 to 2.3) after
6 months of GH therapy (P  0.0004). Group B showed an
increase in height sd score from 3.1 (3.4 to 2.7) to 2.4
(2.8 to 2.2) after 6 months (P  0.0001). The change in
TABLE 1. Baseline clinical characteristics of the study groups
Group A
(n  16; 1 mg GH/m2d)
Group B
(n  20; 2 mg GH/m2d)
Male/female 9/7 11/9
Gestational age (wk) 37.8 (34.1 to 39.2) 38.0 (33.3 to 39.3)
Birth weight SD score 1.8 (3.4 to 1.1) 2.1 (2.6 to 1.3)
Birth length SD score 2.6 (3.4 to 1.6) 2.8 (3.4 to 2.1)
Age at start of GH treatment (yr) 6.2 (5.8 to 7.4) 6.2 (5.4 to 7.7)
Height SD score at start of GH treatment 3.3 (3.4 to 2.8) 3.1 (3.4 to 2.7)
BMI SD score at start of GH treatment 0.8 (2.0 to 0.1) 1.2 (2.2 to 0.7)
Data are expressed as median (interquartile range).
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height sd score was significantly higher in group B than in
group A (P  0.001).
Overnight GH profiles
Table 2 lists the characteristics of the overnightGHprofiles
for both GH dosage groups at baseline and after 6 months.
At baseline, the AUC0, mean, and maximumGH levels were
comparable for group A and B. After 6 months of GH treat-
ment (when a sc GH injectionwas given at 2000 h), theAUC0,
mean, and maximum GH levels increased significantly in
both groups. All values were significantly higher in group B
compared with group A. For example, in group B, mean GH
levels increased from 9.6–64.4 mU/liter, and maximum GH
levels increased from 43.9–161 mU/liter, whereas group A
showed an increase of mean GH levels from 10.8–34.8 mU/
liter and of maximum GH levels from 57.2–104 mU/liter.
Figure 1 depicts the mean serum GH levels of both groups
at each time point during the overnight GH profiles at baseline
TABLE 2. Characteristics of overnight GH release, IGF-I, and IGFBP-3 levels in group A and B at baseline and after 6 months of GH
treatment
Group A (1 mg GH/m2d)
P valuea
Group B (2 mg GH/m2d)
P valuea P valueb
0 Months 6 Months 0 Months 6 Months
AUC0 (mU/liter12 h) 130 (113–150) 428 (344–638) 0.0004 113 (97.4–138) 791 (668–946) 0.0001 0.0009
Mean GH (mU/liter) 10.8 (9.2–12.5) 34.8 (28.2–52.0) 0.0004 9.6 (8.0–11.3) 64.4 (54.6–76.9) 0.0001 0.001
Max GH (mU/liter) 57.2 (44.4–73.5) 104 (94.3–149) 0.002 43.9 (32.0–53.9) 161 (110–206) 0.0002 0.009
GH 40 mU/liter (h) 0.7 (0.1–1.0) 4.5 (2.9–6.4) 0.0007 0.0 (0.0–0.9) 7.3 (6.0–8.7) 0.0001 0.001
GH 20 mU/liter (h) 2.0 (1.7–2.6) 6.5 (5.7–9.2) 0.0004 1.7 (0.8–2.2) 9.3 (7.7–10.7) 0.0001 0.017
IGF-I SD score 1.6 (2.1 to 1.3) 0.2 (0.5 to 0.7 0.0008 1.6 (2.2 to 1.2) 1.5 (0.8–2.1) 0.0001 0.002
IGFBP-3 SD score 1.5 (1.7 to 0.8) 0.2 (0.7 to 0.2) 0.002 1.5 (1.8 to 1.1) 0.5 (0.44–0.68) 0.0001 0.005
IGF-I to IGFBP-3
ratio SD score
1.1 (1.7 to 0.6) 0.3 (0.3 to 1.0) 0.002 1.0 (1.6 to 0.4) 1.4 (0.6–2.1) 0.0002 0.007
Data are expressed as median (interquartile range).
a Compared to baseline.
b Group B vs. A after 6 months of GH treatment.
FIG. 1. Mean GH levels for each time point during an overnight GH profile at baseline and after 6 months of GH treatment.
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and after 6 months. After sc GH injection at 2000 h, GH levels
remainedabove40mU/liter for 7.3h ingroupBcomparedwith
4.5 h in group A (P 0.0008), and above 20 mU/liter for 9.3 h
in group B compared with 6.5 h in group A (P 0.017). Figure
2 shows the individual mean GH levels during the overnight
GH profiles for each child, with the children ranked per group.
DuringGH treatment, awide interindividual variation inmean
GH levels was seen. Two subjects in groupA and one in group
B showed strikingly high mean serum GH levels compared
with the other children of their group.
IGF-I and IGFBP-3 levels and IGF-I to IGFBP-3 ratio
Serum levels of IGF-I and IGFBP-3 and the IGF-I to IGFBP-3
ratio, expressed as sd scores, are shown in Table 2. Baseline
IGF-I and IGFBP-3 sd scores were comparable for groupA and
B and significantly lower than zero (P 0.0001 to 0.0009). After
6 months of GH treatment, the IGF-I and IGFBP-3 sd scores
increased significantly in both GH dosage groups compared
with baseline, but were significantly higher in group B than in
group A. In group B, the IGF-I sd score increased from1.6 to
1.5 and the IGFBP-3 sd score increased lessmarkedly from1.5
to 0.5. Both sd scores were significantly higher than zero (P 
0.005 and 0.009). In contrast, in group A, the IGF-I sd score
increased from1.6 to 0.2 and the IGFBP-3 sd score from1.5
to0.2, bothbeingnot statisticallydifferent fromzeroanymore.
Seventy-fourpercentof the childrenofgroupBhadserumIGF-I
levels in the highest quintile ( 0.84 sd score), and 37% had
levels above 2 sd score compared with only 19% (P  0.0014)
and 6% (P  0.034) of the children of group A, respectively.
At baseline, the IGF-I to IGFBP-3 ratio sd score was sig-
nificant lower than zero in both groups (P  0.002 and
0.0001). After 6months ofGH treatment, the IGF-I to IGFBP-3
ratio sd score increased significantly in both groups com-
pared with baseline, but was significantly higher in group B
than in group A. In group B, there was an increase from1.0
to 1.4, which was significantly higher than zero (P  0.001).
In contrast, in group A, the IGF-I to IGFBP-3 ratio sd score
increased from 1.1 to 0.3 and was no longer statistically
different from zero. Sixty-three percent of children of group
B had an IGF-I to IGFBP-3 ratio in the highest quintile ( 0.84
sd score) and 32% above 2 sd score, comparedwith 25% (P
0.026) and 0% (P  0.015) of the children in group A,
respectively.
At baseline, the IGFBP-3 sd score correlated significantly
with the AUC0 (r  0.48, P  0.003), mean (r  0.51, P 
0.002), and maximum GH levels (r 0.57, P 0.000), but no
correlation was found after 6 months. In contrast, the IGF-I
and IGF-I to IGFBP-3 ratio sd scores did not correlate with
serum GH levels, neither at baseline, nor at 6 months.
Relationship between the growth response and other
variables
Partial correlationsweremade for groupA and B together,
with adjustment for GH dose. The change in height sd score
FIG. 2. Mean GH levels for each individual during an overnight GH profile before and after 6 months of GH treatment.
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correlated significantly with the height sd score at start (r 
0.34, P  0.044), age at start (r  0.50, P  0.002), AUC0
at start (r  0.34, P  0.044), mean GH levels at start (r 
0.36, P  0.034), and the baseline IGF-I (r  0.47, P 
0.004), and IGFBP-3 sd scores (r  0.51, P  0.002). No
significant partial correlation was found between gain in
height sd score and the following parameters: birth weight
and birth length sd score; target height sd score; maximum
GH levels at start; baseline IGF-I to IGFBP-3 ratio sd score;
AUC0 at 6 months; mean and maximum GH levels at 6
months; IGF-I, IGFBP-3, and IGF-I to IGFBP-3 ratio sd scores
at 6 months; and the 6-month changes in GH levels, IGF-I,
IGFBP-3, and IGF-I to IGFBP-3 ratio sd scores.
Using multiple regression, the following variables were
the best predictors of the 6-month increase in height sd score
during GH treatment: GH dose (group B vs. group A) ( 
0.51, P  0.0002), age (in years) at start of the study ( 
0.370, P  0.0043), and IGF-I sd score at start (  0.34,
P  0.0079). These three variables explained 55% of the
variation of the 6-month change in height sd score.
Discussion
Our study shows that short SGA children receiving high-
dose GH treatment (2 mg/m2d) have very high mean serum
GH levels of 64.4 mU/liter during 12 h per day. High-dose
GH treatment also resulted in serum IGF-I levels and an
IGF-I to IGFBP-3 ratio in the highest quintile (0.84 sd score)
in 74 and 63% of the children, respectively.
This is the first report describing serumGH levels after GH
administration in prepubertal short SGA children. We found
great interindividual variations in mean serum GH levels
among the short SGA children in both GH dosage groups.
Comparable individual variations in GH levels after sc GH
injection have previously been reported in GH-deficient chil-
dren and were attributed to different mechanisms of the
degradation of GH at the site of injection or in the circulation
(22). Two children in group A and one child in group B had
extremely high GH levels compared with the other children
in the groups. Higher serum GH levels have been described
when the GH injection was administered im instead of sc
(23). It is possible that the GH administration in these two
children was not completely sc as in the other children, but
partly intramuscular at the time of the overnight profile.
Their IGF-I levelswere not different comparedwith the other
children.
Previous studies concerning GH levels during GH treat-
ment have mainly been performed in healthy adults (24, 25),
GH-deficient patients (12, 23, 26), and in girls with Turner
syndrome (27). The short SGA children in our study showed
remarkably high mean and maximum serum GH levels after
sc GH injection. Vahl et al. (28) found an inverse correlation
between serum GH levels after a single GH dose and age as
well as intraabdominal fat mass. This might partly explain
the higher mean and maximum GH levels in our study
group, which consisted of young prepubertal SGA children
with a reported lower fatmass and a lower BMI sd score than
their peers (29).
In the high-dose group, mean serum GH levels were 64.4
mU/liter during the 12 h of the GH profile, and remained
above 20 mU/liter for more than 9 h, indicating that short
SGA children treated with 2 mg GH/m2d have elevated GH
levels for a great part of the day. At the end of the overnight
GH-profiles, 11 h after the sc GH injection, serum GH re-
turned to near baseline levels in both groups. For compar-
ison, overnight GH levels in normal prepubertal boys and
girls are 10.5 and 10.8 mU/liter, respectively, and increase
during puberty, reaching maximum values of 17.1 mU/liter
in boys and 20 mU/liter in girls (30).
In the 2-mg GH dose group, 63% of the children had IGF-I
levels and 74% an IGF-I to IGFBP-3 ratio in the highest
quintile ( 0.84 sd score) after GH treatment, and approxi-
mately 30% of them even had levels above 2 sd scores. In
contrast, almost all children of the normal GH dose group
had IGF-I levels and/or an IGF-I to IGFBP-3 ratio sd score
within 1 sd score.
In another group of short SGA children receiving 1 and 2
mg GH/m2d, Sas et al. (6) also showed an increase of the
IGF-I sd score up to 1.2 and 1.9 in the first year and up to 1.7
and 2.0 after 5 yr, respectively, indicating that these levels
remain at the same sd level when GH treatment is given for
many years. deZegher et al. (5) reported a 3- to 6-fold increase
of IGF-I levels after 2 yr of high-dose GH treatment with 2
and 3 mg/m2d, respectively. In all reports, there was also a
significant increase of the IGF-I to IGFBP-3 ratio (5, 6).
We found a clear correlation between baseline GH levels
and the baseline IGFBP-3 sd score, but not with the IGF-I sd
score, which is in agreement with previous studies (3, 8, 31).
This might suggest that IGFBP-3 levels are a more valuable
measure for the endogenous GH secretion in short SGA
children.
The 6-month change in height sd score was inversely re-
lated to mean GH levels at start and the baseline IGF-I,
IGFBP-3, and the IGF-I to IGFBP-3 ratio sd scores, indicating
that children with lower levels of GH and IGF-I were more
sensitive to GH treatment. No correlation was found be-
tween the growth response and the increases in GH, IGF-I,
and IGFBP-3 levels. This may suggest a reduced GH and/or
IGF-I receptor sensitivity, particularly in those children with
higher GH and IGF-I levels in combination with a poorer
growth response. Another explanation may be that IGF-I
receptors in some short SGA children are already maximally
stimulated, meaning that a further increase of GH and IGF-I
levels has no extra effect. Previous reports concerning the
relationship between growth response toGH therapy and the
GH/IGF-I axis are contradictory. Some studies suggest that
the catch-up growth during GH treatment is independent of
the GH/IGF-I axis (6, 11, 26). However, other studies have
shown a clear correlation between the growth response and
baseline IGF-I levels (4, 31) or changes in IGF-I levels during
GH treatment (32).
Concern has been expressed regarding the possible det-
rimental effects of persistently high serum levels of GH and
IGF-I (14, 15). Epidemiological studies have suggested that
high serum levels of GH and IGF-I might increase cancer risk
in human beings, especiallywhen IGFBP-3 levels are low (17,
18). Serum IGF-I levels in the upper tertile to quintile have
been associated with increased risk of breast, prostate, and
colon cancer (16–18). These findings were supported by
Renehan et al. (33) who did a systematic review and meta-
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regression analysis of the association between concentrations
of IGF-I and IGFBP-3 levels and cancer risks.
In contrast, low serum levels of GH and IGF-I, as found
in individuals with a T1663A polymorphism in the human
GH1 gene, are associated with a decreased risk of colo-
rectal cancer (34).
Most short SGA children receiving GH treatment with 2
mg/m2d have high GH levels for many hours per day and
IGF-I levels in the upper quintile ( 0.84 sd score). As the
majority of these children will be treated for 10–12 yr until
adult height is reached, serum GH and IGF-I levels will be
elevated during their childhood and adolescence. Children
treated with the higher GH dose for many years might there-
fore be at increased risk for complications in later life.
Recently, GH treatment for short children born SGA with
persistent short stature has been approved by the European
Agency for the Evaluation of Medicinal Products. However,
there is still debate about the optimal GH dose for these
children. In the United States, the higher GH dose of 2 mg/
m2d has been approved by the Food and Drug Adminis-
tration, whereas we have recently shown that treatment with
a GH dose of 1 mg/m2d was as effective as 2 mg/m2d with
regard to reach a normal adult height (11). In a recent epi-
analysis, it has been shown that height gain is less dose
dependent over the long term than over the short term (35).
For that reason, there is no evidence to support long-term
treatmentwith the higher GHdose for all short SGA children
with regard to adult height improvement.
In conclusion, our study shows that GH treatment with 2
mgGH/m2d in short SGA children results in high serumGH
levels for 12 h per day and IGF-I levels and/or an IGF-I to
IGFBP-3 ratio in the highest quintile (0.84 sd score) in 74
and 63% of the children, respectively, whereas treatment
with a dose of 1 mg GH/m2d completely normalizes IGF-I
and IGFBP-3 levels (1 sd score). The long-term risks of high
GH and IGF-I levels in short SGA children are still unknown.
Therefore, we recommend monitoring IGF-I levels during
GH therapy to ensure these remain within the normal range.
GH treatment could be started at a lower dose with indi-
vidual adjustment based on growth response and IGF-I
levels.
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